StockData
Exelixis, Inc. logo

Exelixis, Inc. (EXEL) stock

EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/303% above fair value
$68.29−0.21 (-0.31%)

Close on Nov 18, 2026Market cap $16.66BP/E 20.4Yield –

Exelixis pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Exelixis's pe ratio was 22.2× on Nov 11, 2026, against 18.6× a year earlier. Over the last 5 years it ranged from 15.4× to 85.7×, with a median of 22.2×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202622.2×+3.7
2025Dec 31, 202518.5×−2.9
2024Dec 31, 202421.3×−64.3
2023Dec 29, 202385.7×+68.8
2022Dec 30, 202216.9×−19.0
2021Dec 31, 202135.8×−6.0
2020Dec 31, 202041.8×+32.8
2019Dec 31, 20199.0×−7.6
2018Dec 31, 201816.7×−45.4
2017Dec 29, 201762.0×+52.7
2012Oct 31, 20129.3×–

More Exelixis figures

See a number that looks wrong?